| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $123K | — | — |
| SG&A Expense | -$1K | -382.1% | -118.0% |
| Pre-tax Income | -$149K | -297.1% | -1110.3% |
| Net Income | -$149K | -297.1% | -1110.3% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $3K | +33.1% | -28.1% |
| Current Assets | $3K | +33.1% | -28.1% |
| Total Assets | $3K | +33.1% | — |
| Current Liabilities | $121K | -29.6% | -5.4% |
| Total Liabilities | $121K | -29.6% | — |
| Stockholders' Equity | -$118K |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$272K | — | — |
| Financing Cash Flow | $274K | — | — |
| +30.3% |
| +4.8% |